Trends in Mortality Related to Hepatitis B and C from 1990 to 2019 in the Western Pacific Region
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to analyze the trends in mortality attributed to hepatitis B and C around the Western Pacific region from 1990 to 2019. Methods: We used data from the Global Burden of Disease Study for a systematic analysis. The deaths related to hepatitis B and C were analyzed by age, sex, year, risk factors, geographical location, and Socio-demographic Index (SDI). Results: From 1990 to 2019, the annual total deaths from hepatitis B decreased from 0.266 to 0.210 million and those from hepatitis C increased from 0.119 to 0.142 million in the Western Pacific region. The age-standardized mortality rate (ASMR) of hepatitis B and C decreased by 63.5% and 48.0%, respectively. The declines in the ASMR related to hepatitis B and C were only detected in 12 and two Western Pacific countries, respectively. As the major risk factors, the contribution of alcohol use to hepatitis B deaths was 52% and drug use to hepatitis C was 80%. In males and females, the ASMR attributed to hepatitis B decreased by 61% and 71%, respectively, and the ASMR attributed to hepatitis C decreased by 43% and 55%, respectively. The association between SDI and ASMRs suggested that hepatitis B and C, respectively, showed an overall decline and stable trends as the SDI improved in the Western Pacific region. Conclusions: Although the mortality rate from hepatitis B and C decreased from 1990 to 2019, notable variation was observed among 27 Western Pacific countries. Efforts targeting hepatitis B and C prevention and treatment are still required in this region, especially for the pandemic countries.
Abstract
Background/Aims: This study aimed to analyze the trends in mortality attributed to hepatitis B and C around the Western Pacific region from 1990 to 2019. Methods: We used data from the Global Burden of Disease Study for a systematic analysis. The deaths related to hepatitis B and C were analyzed by age, sex, year, risk factors, geographical location, and Socio-demographic Index (SDI). Results: From 1990 to 2019, the annual total deaths from hepatitis B decreased from 0.266 to 0.210 million and those from hepatitis C increased from 0.119 to 0.142 million in the Western Pacific region. The age-standardized mortality rate (ASMR) of hepatitis B and C decreased by 63.5% and 48.0%, respectively. The declines in the ASMR related to hepatitis B and C were only detected in 12 and two Western Pacific countries, respectively. As the major risk factors, the contribution of alcohol use to hepatitis B deaths was 52% and drug use to hepatitis C was 80%. In males and females, the ASMR attributed to hepatitis B decreased by 61% and 71%, respectively, and the ASMR attributed to hepatitis C decreased by 43% and 55%, respectively. The association between SDI and ASMRs suggested that hepatitis B and C, respectively, showed an overall decline and stable trends as the SDI improved in the Western Pacific region. Conclusions: Although the mortality rate from hepatitis B and C decreased from 1990 to 2019, notable variation was observed among 27 Western Pacific countries. Efforts targeting hepatitis B and C prevention and treatment are still required in this region, especially for the pandemic countries.
참고문헌 (24)
- GBD 2019 Diseases and Injuries Collaborators, "Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet, 396, pp.1204~1222 (2020)
- Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
- Chan PL, "Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020", Glob Health Med, 3, pp.253~261 (2021)
- The Lancet, "Towards elimination of viral hepatitis by 2030", Lancet, 388, pp.308~ (2016)
- Kobayashi H, "Protocol : prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town : the Nagawa project", PLoS One, 16, pp.e0256711~ (2021)
- Cox AL, "Progress towards elimination goals for viral hepatitis", Nat Rev Gastroenterol Hepatol, 17, pp.533~542 (2020)
- Samarasekera U, "Urgent action needed to eliminate viral hepatitis by 2030", Lancet Gastroenterol Hepatol, 6, pp.611~ (2021)
- Zhang S, "Current advances in the elimination of hepatitis B in China by 2030", Front Med, 11, pp.490~501 (2017)
- "Global Burden of Disease Study 2019 (GBD 2019) Socio-Demographic Index (SDI) 1950–2019" (2021)[URL]
- "Where we work" (2019)[URL]
- Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013 : findings from the Global Burden of Disease Study 2013", Lancet, 388, pp.1081~1088 (2016)
- Sun H, "Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017 : results from a global burden of disease study, 2017", Aging(Albany NY), 11, pp.10952~10991 (2019)
- GBD 2016 Mortality Collaborators, "Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1084~1150 (2017)
- GBD 2019 Risk Factors Collaborators, "Global burden of 87risk factors in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet, 396, pp.1223~1249 (2020)
- Hassan B, "A comprehensive study capturing vision loss burden in Pakistan(1990-2025) : findings from the Global Burden of Disease(GBD)2017 study", PLoS One, 14, pp.e0216492~ (2019)
- Wong MC, "The changing epidemiology of liver diseases in the Asia-Pacific region", Nat Rev Gastroenterol Hepatol, 16, pp.57~73 (2019)
- Phan DV, "Liver cancer prediction in a viral hepatitis cohort : a deep learning approach", Int J Cancer, 147, pp.2871~2878 (2020)
- Zhang M, "Changing incidence of reported viral hepatitis in China from 2004 to 2016 : an observational study", BMJ Open, 9, pp.e028248~ (2019)
- Kuo LF, "High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years", Dig Dis Sci, 59, pp.2580~2587 (2014)
- Pugliese N, "Directly acting antivirals are safe and effective in HCV positive patients aged 80years and older : a multicenter real-life study", Expert Opin Drug Saf, 20, pp.839~843 (2021)
- Klimas J, "Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users", Cochrane Database Syst Rev, 12, pp.CD009269~ (2018)
- Zhao Q, "Incidence trend and age-periodcohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017", Medicine(Baltimore), 99, pp.e22005~ (2020)
- Xie M, "Sero-epidemiology study of hepatitis B virus surface antibodies from 2017 to 2019 among Chinese young adults in Hunan Province : a three-year retrospective study", Medicine(Baltimore), 100, pp.e26665~ (2021)
- Shan S, "How to control highly endemic hepatitis B in Asia", Liver Int, 38(Suppl 1), pp.122~125 (2018)